Representative Case Studies
Anonymized examples of the device types, file scopes, timing pressure, and remediation patterns handled across ISO 10993, EU MDR, and FDA projects. These examples are meant to show fit, depth, and workflow, not promise identical external outcomes.
Implants and Sensors
Examples include long-term implant and polymer-coated device work with deeper endpoint and chemistry logic.
FDA Remediation
Active AI-response support where endpoint tables, chemistry framing, and waiver logic needed strengthening.
EU MDR Technical Files
Reviewer-facing sections written for Annex I GSPR 10, lifecycle framing, and residual-risk clarity.
Legacy and Change Work
Gap analyses, material changes, and update projects where the core question was what still represented the device.
Designed to show the kind of work handled, while protecting client confidentiality
Specific company names, submission identifiers, and confidential device details are omitted by default. What remains is the project pattern: the device category, the pressure point, the document scope, and the way the work was sequenced. That is enough for qualified teams to judge fit without overstating certainty or breaching confidentiality.
Confidential by Default
These examples are intentionally anonymized and framed around the work pattern, not the client identity.
Documentation-Focused
The emphasis is on BEP, BER, TRA, remediation, and reviewer-facing narrative work rather than generic consulting activity.
Representative, Not Exhaustive
These are selected examples chosen to show range across device types and submission situations.
NDA-Compatible Discussion
For qualified projects, deeper workflow discussion can be shared under NDA where appropriate.
Anonymized case patterns from recent project types
These are framed around the core documentation and regulatory problem each project needed to solve.
Implantable Biosensor for CE Mark Preparation
Scope: Full BEP and BER package for a long-term implant with multi-endpoint biological evaluation needs.
Pressure point: Implant duration, material profile, and the need to keep endpoint logic, chemistry inputs, and risk-file linkage consistent.
Delivery pattern: The BEP was built first and the BER followed the same logic, so the implant story stayed coherent across the file instead of being assembled section by section.
Vascular Catheter FDA AI Response
Scope: Targeted remediation after FDA raised chemistry and rationale concerns in the 510(k) biocompatibility section.
Pressure point: Active FDA timing pressure, weak endpoint logic, and incomplete chemistry framing for a blood-contacting device.
Delivery pattern: A fast review came first, followed by a focused response package rebuilt around device representation, AET framing, chemistry support, and endpoint-specific rationale.
Legacy BER Upgrade for ISO 10993-1:2025
Scope: Gap analysis and targeted update of an existing BER originally prepared under older framing.
Pressure point: The legacy file did not adequately address lifecycle framing, benefit-risk language, or the role of existing data.
Delivery pattern: The highest-risk sections were identified first, then the BER narrative was updated selectively instead of forcing a full rewrite of every section.
Orthopaedic Fixation Device TRA
Scope: Chemistry-driven toxicological risk assessment for a coated implantable device.
Pressure point: Determining whether low-level compounds required more testing or could be handled through exposure and toxicological reasoning.
Delivery pattern: Chemistry outputs were translated into exposure logic, threshold interpretation, and a decision-ready TRA rather than left as a detached compound list.
Dental Implant EU MDR Technical-File Section
Scope: Drafting the full biocompatibility section for a first-time EU MDR technical-file package.
Pressure point: Pulling BEP, BER, and risk-management logic into one Annex I GSPR 10 narrative without creating contradictions between sections.
Delivery pattern: The biological evaluation logic was consolidated into a technical-file section that could sit cleanly inside the broader MDR package instead of reading like pasted source material.
Catheter Hub Material-Change Re-Evaluation
Scope: ISO 10993 impact assessment after a patient-contacting material change in an already marketed device line.
Pressure point: Deciding whether prior evidence still represented the changed chemistry, process state, and finished-device condition.
Delivery pattern: The change-impact review was used to separate reusable evidence from sections that needed targeted BER revision, avoiding an unnecessary full reset.
Three patterns that matter more than device name or market label
Build
First-time submissions often need the whole documentation path defined clearly from the start: BEP, BER, chemistry logic, and a file structure that reads as one controlled argument.
Fix
Remediation projects usually move faster when the real weakness is identified early instead of rewriting everything at once.
Update
Legacy files and changed-device files often need focused re-evaluation rather than a full reset, but that focus has to be scientifically justified.
What these projects actually changed in the file
These are document-level outcomes, not approval claims. The point is to show what moved from weak or incomplete to structured and usable.
Implant Package Became One Coherent Story
Endpoint strategy, chemistry inputs, and risk-file references were aligned so the implant documentation read as one controlled package instead of disconnected sections.
FDA AI Response Shifted from Generic to Defensible
The response package was rebuilt around AET framing, chemistry support, and endpoint-specific rationale instead of generic waiver language.
Legacy BER Updated Where Review Risk Was Highest
The work focused on lifecycle framing, benefit-risk language, and existing-data logic rather than wasting time rewriting low-risk sections first.
Material-Change Review Clarified Reuse vs Rework
The review separated evidence that still represented the device from sections that needed targeted BER revision, which is often the real decision teams need.
Questions teams usually ask about examples and proof
Why are these case studies anonymized?
Most client work in this area is confidential. The goal is to show scope and fit while protecting sensitive device and submission information.
Can you share exact documents?
Not publicly. For qualified discussions, it may be possible to discuss redacted structure, workflow, and evidence logic under NDA.
Do these examples guarantee the same outcome for another device?
No. They are representative of work type and depth, not guarantees of approval, clearance, or reviewer behavior.
What if our project does not match one of these examples exactly?
That is normal. Most real projects combine elements of more than one pattern, which is why the best next step is usually a scoping discussion.
Have a similar documentation or remediation problem?
Send the device type, pathway, materials context, and current challenge. I will review the fit and tell you the likely scope, priorities, and next step.